ABIVAX Société Anonyme (ABVX)Healthcare | Biotechnology | Paris, France | NasdaqGM
135.98 USD
-3.92
(-2.802%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 136.26 +0.28 (0.206%) ⇧ (July 13, 2026, 7:27 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:28 a.m. EDT
The recent surge in ABVX stock is driven by tangible progress: positive Phase 3 ulcerative colitis data and a successful $800 million capital raise extending cash reserves to 2029. While the company remains unprofitable with negative operating margins and a high price-to-sales multiple, the liquidity position is fortress-like relative to debt. The price has rallied sharply from the mid-$90s to nearly $140 in two weeks, outpacing the broader market and the 200-day average. Options flow confirms this bullish sentiment, with heavy call open interest at 180 and 182.5 strikes. However, the security has too little price history to assess long-term trends reliably, and the long-term investment case relies entirely on the commercialization of the drug. The short-term outlook is strongly positive due to the catalyst, but investors should remain cautious regarding the inherent risks of a pre-revenue biotech firm. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.131112 |
| AutoARIMA | 0.131931 |
| AutoETS | 0.132349 |
| AutoTheta | 0.132804 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 16.12 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.527 |
| Excess Kurtosis | -0.34 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.964 |
| Revenue per Share | 0.067 |
| Market Cap | 11,852,107,776 |
| Forward P/E | -41.66 |
| Beta | -0.21 |
| Website | https://www.abivax.com |
As of July 11, 2026, 6:28 a.m. EDT: Call buyers are aggressive, with significant open interest at 150, 180, and 182.5 strikes, betting on a continued rally. Put sellers are active near the money and below, creating a floor around current levels. Implied volatility is elevated at deep strikes, reflecting the uncertainty surrounding the recent catalyst-driven surge.
| Attribute | Value |
|---|---|
| 52 Week Change | 14.843715 |
| Address1 | 7-11 Boulevard Haussmann |
| All Time High | 148.83 |
| All Time Low | 4.77 |
| Ask | 136.18 |
| Ask Size | 1 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 2,809,920 |
| Average Daily Volume3 Month | 2,063,877 |
| Average Volume | 2,063,877 |
| Average Volume10Days | 2,809,920 |
| Beta | -0.211 |
| Bid | 136.98 |
| Bid Size | 1 |
| Book Value | 6.1868143 |
| City | Paris |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 135.98 |
| Current Ratio | 8.247 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 138.75 |
| Day Low | 134.6 |
| Debt To Equity | 7.964 |
| Earnings Call Timestamp End | 1,712,579,400 |
| Earnings Call Timestamp Start | 1,712,579,400 |
| Earnings Timestamp End | 1,774,296,000 |
| Earnings Timestamp Start | 1,774,296,000 |
| Ebitda | -254,004,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -40.648 |
| Enterprise To Revenue | 2,098.511 |
| Enterprise Value | 10,324,674,560 |
| Eps Current Year | -3.6435 |
| Eps Forward | -3.264 |
| Eps Trailing Twelve Months | -5.25 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 115.1298 |
| Fifty Day Average Change | 20.850197 |
| Fifty Day Average Change Percent | 0.18110165 |
| Fifty Two Week Change Percent | 1,484.3715 |
| Fifty Two Week High | 148.83 |
| Fifty Two Week High Change | -12.850006 |
| Fifty Two Week High Change Percent | -0.08634016 |
| Fifty Two Week Low | 8.11 |
| Fifty Two Week Low Change | 127.869995 |
| Fifty Two Week Low Change Percent | 15.766954 |
| Fifty Two Week Range | 8.11 - 148.83 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,697,808,600,000 |
| Float Shares | 60,564,195 |
| Forward Eps | -3.264 |
| Forward P E | -41.660538 |
| Free Cashflow | -114,471,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 80 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 4,920,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.70619005 |
| Implied Shares Outstanding | 87,160,669 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-10-20 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France. |
| Long Name | ABIVAX Société Anonyme |
| Market | us_market |
| Market Cap | 11,852,107,776 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_256839883 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -332,200,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,198,882,631 |
| Number Of Analyst Opinions | 11 |
| Open | 137.29 |
| Operating Cashflow | -178,370,000 |
| Operating Margins | -41.83705 |
| Payout Ratio | 0.0 |
| Phone | 33 1 53 83 09 63 |
| Post Market Change | 0.27999878 |
| Post Market Change Percent | 0.20591174 |
| Post Market Price | 136.26 |
| Post Market Time | 1,783,985,223 |
| Previous Close | 139.9 |
| Price Eps Current Year | -37.321255 |
| Price Hint | 2 |
| Price To Book | 21.979 |
| Price To Sales Trailing12 Months | 2,408.965 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.072 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.36364 |
| Region | US |
| Regular Market Change | -3.92 |
| Regular Market Change Percent | -2.802 |
| Regular Market Day High | 138.75 |
| Regular Market Day Low | 134.6 |
| Regular Market Day Range | 134.6 - 138.75 |
| Regular Market Open | 137.29 |
| Regular Market Previous Close | 139.9 |
| Regular Market Price | 135.98 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,031,727 |
| Return On Assets | -0.44652 |
| Return On Equity | -1.5706799 |
| Revenue Growth | 0.352 |
| Revenue Per Share | 0.067 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 87,160,669 |
| Shares Percent Shares Out | 0.0542 |
| Shares Short | 4,325,904 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,053,530 |
| Short Name | Abivax SA |
| Short Percent Of Float | 0.054899998 |
| Short Ratio | 1.15 |
| Source Interval | 15 |
| Symbol | ABVX |
| Target High Price | 187.0 |
| Target Low Price | 132.0 |
| Target Mean Price | 161.0 |
| Target Median Price | 160.0 |
| Total Cash | 491,552,000 |
| Total Cash Per Share | 6.199 |
| Total Debt | 34,211,000 |
| Total Revenue | 4,920,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.25 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 113.4958 |
| Two Hundred Day Average Change | 22.4842 |
| Two Hundred Day Average Change Percent | 0.198106 |
| Type Disp | Equity |
| Volume | 1,031,727 |
| Website | https://www.abivax.com |
| Zip | 75,009 |